Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LEXX
stocks logo

LEXX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
50.00K
-72.81%
-0.165
+3.13%
50.00K
-71.26%
-0.150
-0%
50.00K
-71.26%
-0.150
-28.57%
Estimates Revision
The market is revising No Change the revenue expectations for Lexaria Bioscience Corp. (LEXX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 8.74%.
Revenue Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+8.74%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Lexaria Bioscience Corp (LEXX.O) is -2.15, compared to its 5-year average forward P/E of -3.28. For a more detailed relative valuation and DCF analysis to assess Lexaria Bioscience Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.28
Current PE
-2.15
Overvalued PE
-0.54
Undervalued PE
-6.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.90
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.01
Undervalued EV/EBITDA
-2.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
45.53
Current PS
0.00
Overvalued PS
72.29
Undervalued PS
18.78
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LEXX News & Events

Events Timeline

(ET)
2025-11-12
09:13:34
Lexaria Bioscience Expands Material Transfer Agreement with Pharmaceutical Firm
select
2025-10-14 (ET)
2025-10-14
16:03:07
Lexaria Bioscience Seeks Approval to Sell 2.76 Million Shares of Common Stock for Shareholders
select
2025-10-09 (ET)
2025-10-09
09:23:10
Lexaria Bioscience Partners with Advisory Firm to Explore New Business Opportunities
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
09-27Benzinga
Nasdaq Rises by 100 Points as US Consumer Sentiment Declines

  • U.S. Stock Market Performance: U.S. stocks saw gains, with the Dow up 0.83%, Nasdaq rising 0.45%, and S&P 500 increasing by 0.62%. Energy shares led the sector gains, while information technology stocks fell by 0.4%.

  • Consumer Sentiment and Economic Indicators: The University of Michigan's consumer sentiment was revised down to 55.1 for September, and personal spending rose by 0.6% in August, exceeding market expectations. The Personal Consumption Expenditures price index showed a year-over-year increase of 2.7%.

  • Notable Stock Movements: MEDIROM Healthcare Technologies saw a 106% increase in shares after expansion plans, while bioAffinity Technologies surged 73% following positive case studies. Conversely, Pop Culture Group's shares dropped 53% due to a direct offering.

  • Global Market Trends: European shares rose, with the eurozone's STOXX 600 gaining 0.66%, while Asian markets closed lower, with Japan's Nikkei 225 down 0.87%.

[object Object]
Preview
4.5
09-26Benzinga
Dow Rises More Than 250 Points as Fed's Main Inflation Indicator Stays Elevated

  • U.S. Stock Market Performance: U.S. stocks saw gains, with the Dow Jones rising over 250 points, while the NASDAQ and S&P 500 also experienced increases. Energy shares led the sector gains, while consumer staples saw a slight decline.

  • Inflation and Economic Indicators: The Federal Reserve's preferred inflation gauge, the Personal Consumption Expenditures price index, rose to 2.7% year-over-year in August, raising concerns about the sustainability of aggressive rate-cut bets. Personal spending and income also showed positive growth.

  • Notable Stock Movements: MEDIROM Healthcare Technologies saw a significant stock increase of 155% after expansion plans, while bioAffinity Technologies surged 92% following positive case study results. Conversely, Pop Culture Group's shares dropped 52% due to a direct offering.

  • Global Market Trends: European shares rose, with the eurozone's STOXX 600 gaining 0.8%, while Asian markets closed lower, with Japan's Nikkei 225 and Hong Kong's Hang Seng both declining.

[object Object]
Preview
2.0
09-26Benzinga
Top KingWin Shares Surge 87%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Top KingWin Ltd Surge: Shares of Top KingWin Ltd rose 87.4% to $5.92 in pre-market trading after announcing a sales contract for 10,000 TK-D2C AI Robots with Walker Times International.

  • Other Notable Gainers: MEDIROM Healthcare Technologies saw a 242% increase, while New Era Energy & Digital surged 37.6%, and Datavault AI gained 33% following significant announcements and investments.

  • Significant Losers: Kuke Music Holding dipped 30.5% after acquiring a controlling interest in Naxos Music Group, and Concentrix Corporation fell 20.5% due to disappointing earnings results.

  • Market Overview: The pre-market trading session showed a mix of gains and losses among various stocks, with notable movements in both directions across the board.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lexaria Bioscience Corp (LEXX) stock price today?

The current price of LEXX is 1.12 USD — it has increased 0.9 % in the last trading day.

arrow icon

What is Lexaria Bioscience Corp (LEXX)'s business?

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.

arrow icon

What is the price predicton of LEXX Stock?

Wall Street analysts forecast LEXX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEXX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lexaria Bioscience Corp (LEXX)'s revenue for the last quarter?

Lexaria Bioscience Corp revenue for the last quarter amounts to 174.00K USD, increased 107.14 % YoY.

arrow icon

What is Lexaria Bioscience Corp (LEXX)'s earnings per share (EPS) for the last quarter?

Lexaria Bioscience Corp. EPS for the last quarter amounts to -0.14 USD, decreased -0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lexaria Bioscience Corp (LEXX)'s fundamentals?

The market is revising No Change the revenue expectations for Lexaria Bioscience Corp. (LEXX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 8.74%.
arrow icon

How many employees does Lexaria Bioscience Corp (LEXX). have?

Lexaria Bioscience Corp (LEXX) has 7 emplpoyees as of December 05 2025.

arrow icon

What is Lexaria Bioscience Corp (LEXX) market cap?

Today LEXX has the market capitalization of 25.34M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free